Shares of Sanofi (EPA:SAN) have earned an average rating of “Hold” from the sixteen brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is €87.69 ($104.39).
SAN has been the subject of several research reports. set a €81.00 ($96.43) price objective on Sanofi and gave the company a “neutral” rating in a research report on Wednesday, August 30th. Jefferies Group set a €87.00 ($103.57) target price on Sanofi and gave the stock a “neutral” rating in a research report on Thursday, August 24th. J P Morgan Chase & Co reaffirmed a “neutral” rating and issued a target price on shares of Sanofi in a research report on Thursday, November 2nd. S&P Global set a €83.00 ($98.81) target price on Sanofi and gave the stock a “neutral” rating in a research report on Friday, November 3rd. Finally, Citigroup set a €88.00 ($104.76) target price on Sanofi and gave the stock a “neutral” rating in a research report on Friday, October 6th.
Shares of Sanofi (EPA SAN) opened at €73.37 ($87.35) on Thursday. Sanofi has a one year low of €72.92 ($86.81) and a one year high of €92.97 ($110.68).
COPYRIGHT VIOLATION NOTICE: “Sanofi (SAN) Receives Average Rating of “Hold” from Analysts” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.com-unik.info/2017/12/07/sanofi-san-receives-average-rating-of-hold-from-analysts.html.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
What are top analysts saying about Sanofi? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sanofi and related companies.